2024 Meeting Materials, Vaccines and Related Biological Products Advisory Committee
December 12, 2024
The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing and/or video conferencing platform.
On December 12, 2024, under Topic I, the committee will meet in open session to discuss Considerations for Respiratory Syncytial Virus [RSV] Vaccine Safety in Pediatric Populations.
Under Topic II, the committee will meet in open session to hear overviews of the Laboratory of Immunoregulation (LI) and Laboratory of Retroviruses (LR) research programs in the Division of Viral Products (DVP), Office of Vaccines Research and Review (OVRR), Center for Biologics Evaluation and Research (CBER). After the open session ends for Topic II, the meeting will be closed to the public for committee deliberations.
October 10, 2024
The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing and/or video conferencing platform.
On October 10, 2024, under Topic 1, the committee will discuss and make recommendations on the strain selection for the influenza virus vaccines for the 2025 southern hemisphere influenza season.
Under Topic II, the committee will discuss pandemic preparedness for highly pathogenic avian influenza virus including considerations for vaccine composition for (H5) vaccines. Under Topic III, under open session, the committee will hear an overview of the research programs in the Laboratory of Pediatric & Respiratory Viral Diseases (LPRVD) and the Laboratory of DNA Viruses (LDNAV) in the Division of Viral Products (DVP), Office of Vaccines Research and Review (OVRR), Center for Biologics Evaluation and Research (CBER).
September 20, 2024
The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing and/or video conferencing platform.
On September 20, 2024, under Topic I, the committee will meet in open session to discuss considerations related to the use of pertussis Controlled Human Infection Models (CHIMs) in pivotal studies to demonstrate efficacy of pertussis vaccines for the purpose of licensure.
Under Topic II, the committee will meet in open session to hear an overview of the Laboratory of Mucosal Pathogens and Cellular Immunology (LMPCI) research program in the Division of Bacterial, Parasitic, and Allergenic Products, Office of Vaccines Research and Review, and CBER. After the open session, the meeting will be closed to the public for committee deliberations.
June 5, 2024
The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform.
On June 5, 2024, the Committee will meet in open session to discuss and make recommendations on the selection of strain(s) to be included in the 2024-2025 Formula for COVID-19 vaccines.
Postponed - May 16, 2024
The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform.
On May 16, 2024, the Committee will meet in open session to discuss and make recommendations on the selection of strain(s) to be included in the 2024-2025 Formula for COVID-19 vaccines.
March 5, 2024
The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform.
On March 5, 2024, the committee will meet in open session to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2024 to 2025 influenza season.